...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Microbiology >Serogroup-Specific Bacterial Engineered Glycoproteins as Novel Antigenic Targets for Diagnosis of Shiga Toxin-Producing-Escherichia coli-Associated Hemolytic-Uremic Syndrome
【24h】

Serogroup-Specific Bacterial Engineered Glycoproteins as Novel Antigenic Targets for Diagnosis of Shiga Toxin-Producing-Escherichia coli-Associated Hemolytic-Uremic Syndrome

机译：血清群特异性细菌工程糖蛋白作为新型志贺靶点的志贺毒素生产大肠杆菌相关的溶血性尿毒症综合征的诊断。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Human infection with Shiga toxin-producing Escherichia coli (STEC) is a major cause of postdiarrheal hemolytic-uremic syndrome (HUS), a life-threatening condition characterized by hemolytic anemia, thrombocytopenia, and acute renal failure. E. coli O157:H7 is the dominant STEC serotype associated with HUS worldwide, although non-O157 STEC serogroups can cause a similar disease. The detection of anti-O157 E. coli lipopolysaccharide (LPS) antibodies in combination with stool culture and detection of free fecal Shiga toxin considerably improves the diagnosis of STEC infections. In the present study, we exploited a bacterial glycoengineering technology to develop recombinant glycoproteins consisting of the O157, O145, or O121 polysaccharide attached to a carrier protein as serogroup-specific antigens for the serological diagnosis of STEC-associated HUS. Our results demonstrate that using these antigens in indirect ELISAs (glyco-iELISAs), it is possible to clearly discriminate between STEC O157-, O145-, and O121-infected patients and healthy children, as well as to confirm the diagnosis in HUS patients for whom the classical diagnostic procedures failed. Interestingly, a specific IgM response was detected in almost all the analyzed samples, indicating that it is possible to detect the infection in the early stages of the disease. Additionally, in all the culture-positive HUS patients, the serotype identified by glyco-iELISAs was in accordance with the serotype of the isolated strain, indicating that these antigens are valuable not only for diagnosing HUS caused by the O157, O145, and O121 serogroups but also for serotyping and guiding the subsequent steps to confirm diagnosis.
机译：人类感染产生志贺毒素的大肠杆菌（STEC）是导致腹泻后溶血性尿毒症综合征（HUS）的主要原因，该病是威胁生命的疾病，其特征在于溶血性贫血，血小板减少和急性肾衰竭。大肠杆菌O157：H7是全球范围内与HUS相关的主要STEC血清型，尽管非O157 STEC血清群可引起类似的疾病。抗O157大肠杆菌脂多糖（LPS）抗体的检测与粪便培养相结合以及游离粪便志贺毒素的检测大大改善了STEC感染的诊断。在本研究中，我们利用细菌糖工程技术开发了由O157，O145或O121多糖组成的重组糖蛋白，该多糖与作为血清群特异性抗原的载体蛋白相连，用于血清学诊断STEC相关HUS。我们的结果表明，在间接ELISA（glyco-iELISA）中使用这些抗原，可以清楚地区分STEC O157-，O145-和O121感染的患者和健康的儿童，并确定HUS患者的诊断为经典诊断程序失败的人。有趣的是，在几乎所有分析的样品中都检测到了特定的IgM反应，这表明有可能在疾病的早期阶段检测到感染。此外，在所有培养阳性的HUS患者中，通过糖化iELISA鉴定出的血清型与分离株的血清型一致，表明这些抗原不仅对诊断由O157，O145和O121血清型引起的HUS具有价值。而且还可以进行血清分型，并指导后续步骤以确诊。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号